These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 21620043)

  • 1. Switch from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in kidney transplantation.
    Iaria G; Sforza D; Angelico R; Toti L; de Luca L; Manuelli M; Bellini I; Manzia TM; Anselmo A; Tisone G
    Transplant Proc; 2011 May; 43(4):1028-9. PubMed ID: 21620043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment.
    Ma MK; Kwan LP; Mok MM; Yap DY; Tang CS; Chan TM
    Ren Fail; 2013 Aug; 35(7):942-5. PubMed ID: 23815459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation.
    Calia R; Lai C; Aceto P; Luciani M; Romagnoli J; Lai S; Gargiulo A; Citterio F
    Transplant Proc; 2011 May; 43(4):1020-3. PubMed ID: 21620041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure.
    Hougardy JM; Broeders N; Kianda M; Massart A; Madhoun P; Le Moine A; Hoang AD; Mikhalski D; Wissing KM; Abramowicz D
    Transplantation; 2011 Mar; 91(5):566-9. PubMed ID: 21192316
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early conversion from twice-daily tacrolimus to once-daily extended formulation in renal transplant patients before hospital discharge.
    Jannot M; Masson I; Alamartine E; Mariat C
    Ann Transplant; 2014 Jul; 19():320-4. PubMed ID: 24999809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion to prolonged release tacrolimus formulation in stable kidney transplant recipients.
    Wu SW; Tsai HC; Tsai PY; Hung TW; Chang HR; Lian JD
    Swiss Med Wkly; 2013; 143():w13850. PubMed ID: 23986367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome.
    Perrakis A; Schwarz K; Yedibela S; Croner RS; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3702-7. PubMed ID: 22172830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients.
    Comuzzi C; Lorenzin D; Rossetto A; Faraci MG; Nicolini D; Garelli P; Bresadola V; Toniutto P; Soardo G; Baroni GS; Adani GL; Risaliti A; Baccarani U
    Transplant Proc; 2010 May; 42(4):1320-1. PubMed ID: 20534291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of conversion from Advagraf to twice-daily generic tacrolimus in kidney transplant recipients: a single-center study.
    Melo MJ; Gonçalves J; Guerra JO; Santana A; Nascimento C
    Transplant Proc; 2015 May; 47(4):911-3. PubMed ID: 26036484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from twice-daily to once-daily extended-release tacrolimus in renal transplant recipients: 2-year results and review of the literature.
    Tran D; Vallée M; Collette S; Senécal L; Lafrance JP; Dandavino R; Boucher A
    Exp Clin Transplant; 2014 Aug; 12(4):323-7. PubMed ID: 24844288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A; Poli L; Nofroni I; Bachetoni A; Tinti F; Umbro I; Barile M; Berloco PB; Mitterhofer AP
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study.
    Krämer BK; Charpentier B; Bäckman L; Silva HT; Mondragon-Ramirez G; Cassuto-Viguier E; Mourad G; Sola R; Rigotti P; Mirete JO;
    Am J Transplant; 2010 Dec; 10(12):2632-43. PubMed ID: 20840480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
    Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
    Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels.
    Crespo M; Mir M; Marin M; Hurtado S; Estadella C; Gurí X; Rap O; Moral R; Puig JM; Lloveras J
    Transplant Proc; 2009; 41(6):2115-7. PubMed ID: 19715848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once- versus twice-daily tacrolimus: are the formulations truly equivalent?
    Barraclough KA; Isbel NM; Johnson DW; Campbell SB; Staatz CE
    Drugs; 2011 Aug; 71(12):1561-77. PubMed ID: 21861541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited sampling strategies for tacrolimus exposure (AUC0-24) prediction after Prograf(®) and Advagraf(®) administration in children and adolescents with liver or kidney transplants.
    Almeida-Paulo GN; Lubomirov R; Alonso-Sanchez NL; Espinosa-Román L; Fernández Camblor C; Díaz C; Muñoz Bartola G; Carcas-Sansuán AJ
    Transpl Int; 2014 Sep; 27(9):939-48. PubMed ID: 24861353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.